Floatz logo

24 assets in Plasmablastic Lymphoma

Therapeutic assets addressing Plasmablastic Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Adriamycin
Plasmablastic Lymphoma
National Cancer Institute (NCI)P2BB (68)
Etoposide
Plasmablastic Lymphoma
National Cancer Institute (NCI)P2BB (68)
Prednisone
Plasmablastic Lymphoma
National Cancer Institute (NCI)P2BB (68)
Cyclophosphamide
Plasmablastic Lymphoma
National Cancer Institute (NCI)P2BB (67)
(+)-Vincristine
Plasmablastic Lymphoma
National Cancer Institute (NCI)P2BB (67)
Rituximab
Plasmablastic Lymphoma
National Cancer Institute (NCI)P2BB (65)
Daratumumab
Plasmablastic Lymphoma
Fondazione Italiana Linfomi - ETSP2B (58)
Dexasone
Plasmablastic Lymphoma
Fondazione Italiana Linfomi - ETSP2B (58)
Vincristine Sulfate
Plasmablastic Lymphoma
National Cancer Institute (NCI)P1/2B (58)
Elranatamab
Plasmablastic Lymphoma
University of Illinois at ChicagoP2/3CCC (55)
Lentivirus Vector Rhiv7-Shi-Tar-Ccr5Rz-Transduced Hematopoietic Stem/Progenitor Cells
Plasmablastic Lymphoma
AIDS Malignancy ConsortiumP1/2CCC (54)
Bortezomib
Plasmablastic Lymphoma
Fondazione Italiana Linfomi - ETSP2CCC (53)
Nivolumab
Plasmablastic Lymphoma
National Cancer Institute (NCI)P2CCC (53)
Camustine
Plasmablastic Lymphoma
AIDS Malignancy ConsortiumP1/2CC (45)
Cytarabine
Plasmablastic Lymphoma
AIDS Malignancy ConsortiumP1/2CC (45)
Lentivirus Vector Ccr5 Shrna
Plasmablastic Lymphoma
AIDS Malignancy ConsortiumP1/2CC (45)
Melphalan
Plasmablastic Lymphoma
AIDS Malignancy ConsortiumP1/2CC (45)
Immunoglobulin G1, Anti-(Human Cd Antigen Cd27) (Human Monoclonal Cdx-1127 Clone 1F5 Heavy Chain), Disulfide With Human Monoclonal Cdx-1127 Clone 1F5 .Kappa.-Chain, Dimer
Plasmablastic Lymphoma
National Cancer Institute (NCI)P2CC (44)
Busulfanum
Plasmablastic Lymphoma
City of Hope Medical CenterP1CC (43)
Nivestim
Plasmablastic Lymphoma
City of Hope Medical CenterP1CC (43)
Teclistamab
Plasmablastic Lymphoma
National Cancer Institute (NCI)P1CC (43)
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)
Plasmablastic Lymphoma
National Cancer Institute (NCI)P1CC (41)
Pomalidomide
Plasmablastic Lymphoma
National Cancer Institute (NCI)P1CC (41)
Sgr-1505
Plasmablastic Lymphoma
Schrödinger, Inc.P1CC (41)